A phase III study to evaluate the safety and efficacy of Cyclobenzaprine (TNX-102 SL) in patients with post traumatic stress disorders
Phase of Trial: Phase III
Latest Information Update: 22 Sep 2016
At a glance
- Drugs Cyclobenzaprine (Primary)
- Indications Post-traumatic stress disorders
- Focus Registrational; Therapeutic Use
- 22 Sep 2016 New trial record
- 29 Aug 2016 According to a Tonix Pharmaceuticals Holding Corp media release, the company expects to initiate this study later in the year 2017.
- 29 Aug 2016 According to a Tonix Pharmaceuticals Holding Corp media release, data from this study will support the planned New Drug Application (NDA).